evipedia.ai
← Back

Prostamax for Health & Longevity

Evidence Review created on 09/29/2026 using AI4L / Opus 5.5

Also known as: KEDP, Lys-Glu-Asp-Pro, Lysyl-Glutamyl-Aspartyl-Proline, H-Lys-Glu-Asp-Pro-OH, Prostomax, Prostamaks

Motivation

Prostamax is a synthetic peptide made of four amino acids, designed in Russia to act on the prostate gland. It belongs to the family of “peptide bioregulators” developed by the Russian ageing researcher Vladimir Khavinson, which are proposed to switch back on genes that become silenced with age. Prostate enlargement and chronic pelvic pain affect a large share of men past midlife, so an agent claimed to restore prostate tissue rather than only relieve symptoms attracts men focused on long-term health.

The peptide was modelled on an older extract taken from bull prostates that has been used by Russian prostate specialists for decades. Over the past several years, Prostamax has moved from specialist Russian research into the online market for injectable research peptides, where it is sold alongside other bioregulators to longevity-minded men.

This review examines what is known about Prostamax: how it is proposed to work, the laboratory, animal and human evidence behind its claimed benefits, its known and theoretical risks, how it is used in practice, and the quality and independence of its evidence base.

Benefits - Risks - Protocol - Conclusion

This section lists overview content on Prostamax and on the Khavinson peptide-bioregulator class it belongs to.

No directly relevant content was found from Rhonda Patrick, Peter Attia, Chris Kresser, Life Extension Magazine or Lifespan.io: their site searches for “Prostamax” and “bioregulator” returned nothing, and Lifespan.io’s only Khavinson-related article concerns Epitalon and egg-cell aging, not the prostate or the bioregulator concept. Andrew Huberman’s only related content is a brief segment on the sibling peptides Pinealon and Epitalon for sleep within a general peptide-therapy episode, too limited to qualify. Only four items are listed because most other Prostamax content consists of vendor product pages.

Grokipedia

  • Prostamax

    An AI-generated overview collecting the Prostamax cell, animal and patent toxicity data plus regulatory status; useful as an index, although many of its references are vendor product pages.

Examine

No Examine article on Prostamax exists. Examine.com does not typically cover research-only injectable peptides that lack human trials.

ConsumerLab

No ConsumerLab article on Prostamax exists. ConsumerLab does not test research-grade injectable peptides.

Systematic Reviews

The only systematic review touching Prostamax covers short-peptide gene regulation broadly; none addresses its clinical benefits or risks.

No systematic review or meta-analysis exists on Prostamax’s claimed prostate benefits or on its principal risks (unregulated product quality and unknown long-term safety); both sides of the trade-off are unrepresented.

Mechanism of Action

Prostamax is the tetrapeptide KEDP (lysine–glutamic acid–aspartic acid–proline), designed from the amino acid composition of Prostatilen, a bovine prostate extract. Its developers propose that it enters cells through PEPT1 and LAT1/LAT2 (membrane transporters that carry small peptides and amino acids into cells), reaches the nucleus, and binds DNA and histones (the proteins DNA is wound around). In computer docking it fitted these transporters, and in DNA melting experiments it altered double-helix stability. The claimed result is loosening of heterochromatin (densely packed, silenced DNA), reactivating age-silenced genes and producing anti-inflammatory and tissue-repair effects in prostate and bladder.

A competing view holds that unmodified short peptides are cut apart by peptidases (protein-cutting enzymes) in blood and tissue within minutes, that no receptor has been identified, and that tissue specificity has never been shown with independent tracer studies, so reported effects may reflect assay artefacts or released amino acids.

  • Half-life: not measured; comparable short peptides clear from plasma within minutes.
  • Selectivity: claimed prostate and bladder specificity; no receptor identified.
  • Tissue distribution: unstudied; small (487.5 daltons) and water-soluble.
  • Metabolism: hydrolysis to free amino acids by peptidases; no involvement of CYP enzymes (cytochrome P450, the liver’s main drug-processing enzymes) is expected.

Historical Context & Evolution

Prostamax was originally intended as a prescription treatment for chronic prostatitis and early prostate enlargement. It grew out of Soviet military-medicine research: in the 1970s, Vladimir Khavinson and his colleague V. G. Morozov at the Kirov Military Medical Academy in Leningrad began isolating peptide mixtures from animal organs, called cytomedins, to restore organ function. Their bull-prostate extract Prostatilen was tested clinically by the early 1990s, with early case series co-authored by Khavinson reporting symptom relief in 96.7% of 307 men with chronic prostatitis, and its successors Vitaprost and Samprost remain in Russian urology practice.

Because extracts vary between batches and may provoke allergic reactions, Khavinson’s St. Petersburg Institute of Bioregulation and Gerontology designed short synthetic peptides from each extract’s amino acid composition. The prostate tetrapeptide was patented in 2002 (WO2002066497); the patent reports no toxicity in animal studies and symptom and urine-flow improvement in two small non-randomized patient series. Commercial development passed to the St. Petersburg company Geropharm, whose employee co-authored the 2013 rat study, and a 2017 patent covers rectal suppositories.

Interest from longevity-oriented men grew in the 2010s–2020s, when Western “research peptide” vendors began selling Khavinson peptides and podcasts popularized the bioregulator concept alongside the developer’s “peptide theory of ageing”. What changed was access rather than evidence: the peptide has never entered a registered human trial, the original clinical series remain unpublished outside the patent, and no independent group has tested its specific effects in people. Neither side has produced data that settle the question.

Expected Benefits

High 🟩 🟩 🟩

No benefit reaches High: the only human data on Prostamax are two small non-randomized patient series with conventional-treatment comparison groups, described only in a patent, and no randomized human trial of the synthetic peptide has been published.

Medium 🟩 🟩

No benefit reaches Medium: there is no single peer-reviewed controlled human trial of Prostamax, and the controlled trials that exist tested bovine prostate extracts rather than the synthetic tetrapeptide.

Low 🟩

Relief of Chronic Prostatitis and Urinary Symptoms

Reported relief of pelvic pain and urinary symptoms in chronic prostatitis and early benign prostatic hyperplasia. Human data are two non-randomized series in the developer’s patent. Rats showed less prostate inflammation and smaller enlarged prostates. Controlled human support is indirect, from an oral Vitaprost randomized controlled trial.

Magnitude: In the patent series, pain resolved in 64.0% and decreased in a further 32.7% of 35 men with chronic prostatitis; in the extract trial, oral Vitaprost roughly halved the probability of prostatitis flare-ups.

Improved Sexual Function in Chronic Prostatitis

Men with prostatitis-related erectile or libido complaints reported improvement after injection courses. Evidence is the non-randomized series in the developer’s patent plus increased mating behaviour in rats. The parent extract Prostatilen reported similar effects in clinical series co-authored by its developer.

Magnitude: In the patent series, 44.4% of men with impaired sexual function reported full recovery and 41.8% improvement; no validated erectile-function score was used.

Speculative 🟨

Chromatin Loosening in Aged Immune Cells

In white blood cells from people aged 75–88, Prostamax loosened packed chromatin and activated ribosomal genes (genes for the cell’s protein-making machinery) in cell culture. Basis is in-vitro only.

Prostate Tissue Growth Support in Organ Culture

At 0.05 ng/mL, Prostamax stimulated growth of prostate tissue fragments from young and old rats in organ culture, read by its authors as reparative. Basis is in-vitro only.

Antioxidant Enzyme Support in Aged Rats

In 24-month-old rats, 10 days of injections lowered lipid-oxidation products and raised antioxidant enzyme activity in liver and brain, per the developer’s patent. Basis is animal biomarkers not validated against outcomes.

Lifespan Extension

No lifespan study of Prostamax exists. The claim rests on analogy with other Khavinson peptides that extended rodent lifespan, as summarized in the developer’s review. Basis is extrapolation only.

Benefit-Modifying Factors

  • Genetic polymorphisms: None studied. Variants in SLC15A1 (the gene encoding the PEPT1 peptide transporter) could in theory alter uptake of oral forms; injected forms bypass intestinal transport.
  • Baseline biomarkers: Men with elevated IPSS (International Prostate Symptom Score, a validated 0–35 urinary questionnaire) above 7 or reduced urine flow have measurable room to improve; men with normal scores and flow have no measurable target.
  • Sex: Prostamax targets the prostate and has only been studied in males; no rationale or data exist for use in women.
  • Pre-existing conditions: Reported responses came from chronic prostatitis and early prostate enlargement. The patent notes weaker response in late-stage disease with bladder-neck scarring, and men with prostate cancer are entirely outside the evidence.
  • Age: Patent series covered ages 23–67, while cell studies used donors aged 75–88. Men over 70, often the most interested, have no clinical data, and advanced age-related enlargement is more fibrotic (scarred) and may respond less.

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: no controlled human trial of Prostamax has been published, so there are no replicated human adverse-event data.

Medium 🟥 🟥

No risk reaches Medium: there is no single controlled human trial or consistent observational dataset recording adverse events with the synthetic peptide.

Low 🟥

Speculative 🟨

Contaminated or Mislabeled Research-Grade Product

Sold only as an unregulated research chemical, Prostamax has unverified identity, dose and sterility. Comparable online peptides showed low purity and arsenic and endotoxin (a fever-causing bacterial toxin). Basis is product analyses only.

Possible DNA-Damage Signal From Increased Chromosome Exchanges

In aged donors’ white blood cells, Prostamax doubled sister chromatid exchanges (DNA strand swaps, a standard marker of DNA damage) (Dzhokhadze et al., 2012). Its authors read this as beneficial. Basis is in-vitro only.

Proliferative Signal in Prostate Tissue ⚠️ Conflicted

Prostamax stimulated rat prostate tissue growth in culture, a concern in a cancer-prone gland. Yet it shrank the prostate in a rat enlargement model. Net reading: animal data conflict, so any human effect is unknown.

Increased Bruising or Bleeding Tendency

Prostate peptide extracts, the parent class of Prostamax, raised the anti-platelet activity of blood-vessel walls in rats without changing coagulation. KEDP itself is untested. Basis is animal data from the extract class only.

Delayed Diagnosis of Serious Prostate Disease

Self-treating urinary symptoms with an unproven agent may delay diagnosis of prostate cancer, infection or urinary obstruction. No Prostamax-specific cases are reported; basis is inference from how symptoms are managed.

Injection-Site Reactions and Infection

Self-injection can cause local pain, bruising or abscess, especially with non-sterile reconstitution. No Prostamax-specific reports exist; basis is general experience with self-injected peptides.

Allergic Reactions

The developer’s patent cites possible allergenic effects of the parent bovine extract. A synthetic tetrapeptide is less likely to provoke allergy, and no reactions are reported. Basis is a theoretical concern for the parent extract.

Unknown Long-Term Toxicity in Humans

The patent reports no organ damage in rats dosed for six months at up to 1 mg/kg. No human data beyond 40-day courses exist; basis is animal toxicology.

Risk-Modifying Factors

  • Genetic polymorphisms: No pharmacogenetic data exist. Carriers of BRCA2 (a DNA-repair gene) or HOXB13 (a prostate-development gene) variants have higher prostate cancer risk, magnifying consequences of any growth signal or delayed diagnosis.
  • Baseline biomarkers: Elevated or rising PSA (prostate-specific antigen, a blood marker of prostate enlargement, inflammation or cancer) or a high post-void residual (urine left in the bladder after voiding) signal disease that self-treatment could mask.
  • Sex: Only men have been studied; female use lacks any safety data, including in pregnancy or breastfeeding.
  • Pre-existing conditions: Bleeding disorders or anticoagulant (blood-thinning drug) use (prostate peptide extracts increased vessel-wall anti-platelet (anti-clotting) activity in rats), immune suppression (injection infection risk) and prior peptide allergy raise risk.
  • Age: Men over 60 carry higher background rates of prostate cancer and urinary retention, so masked symptoms matter more; skin and immune healing after injections also slow with age.

Key Interactions & Contraindications

  • Anticoagulants and antiplatelet drugs (blood thinners: warfarin, apixaban, clopidogrel): Caution. Prostate peptide extracts increased vessel-wall anti-platelet activity in rats; KEDP is untested. Possible added bruising or bleeding; mitigation is bruising checks, plus INR (a clotting-time test) on warfarin.
  • Alpha-blockers (drugs relaxing prostate and bladder-neck muscle: tamsulosin, alfuzosin): Monitor. No interaction data; overlapping symptom effects may add and prevent attribution. Stable doses during a course preserve attribution.
  • 5-alpha-reductase inhibitors (drugs blocking conversion of testosterone to dihydrotestosterone: finasteride, dutasteride): Monitor. These roughly halve PSA, so PSA changes cannot be credited to Prostamax. Stable regimens and doubling measured PSA preserve interpretation.
  • Testosterone therapy (testosterone cypionate, testosterone gel): Monitor. Testosterone can raise PSA and prostate volume, confounding assessment and theoretically adding to any growth signal. Mitigation is a PSA test before and 3 months after starting either.
  • PEPT1-transported drugs (valacyclovir, cephalexin, enalapril): Monitor (theoretical, oral forms only). Docking predicts KEDP binds PEPT1 more strongly than known inhibitors, possibly reducing absorption. Mitigation is separating oral doses by at least 2 hours.
  • NSAIDs (non-steroidal anti-inflammatory drugs, common pain relievers: ibuprofen, naproxen) and aspirin: Caution. Theoretical additive anti-platelet effect with increased injection-site bruising. Mitigation is the lowest effective dose during courses.
  • Decongestants and sedating antihistamines (cold and allergy medicines: pseudoephedrine, diphenhydramine): Monitor. They can worsen urine flow or trigger urinary retention in prostate enlargement, mimicking treatment failure. Mitigation is avoiding them during symptom-assessment windows.
  • Supplements with additive prostate effects (saw palmetto, beta-sitosterol, pygeum, pumpkin seed oil, zinc): Monitor. Additive symptom effects possible; no harmful interaction known. Introducing one agent at a time allows attribution of response.
  • Supplements with anti-platelet effects (fish oil, ginkgo, high-dose vitamin E): Caution. Theoretical additive bleeding with the anti-platelet activity reported for the extract class. Mitigation is bruising checks.
  • Other bioregulators (Libidon, Prostalamin, Vesugen, Pinealon): Monitor. Commonly stacked, with no combination data; overlapping claimed mechanisms prevent attribution of benefit or harm. Staggered courses preserve attribution.
  • Prostate biopsy or surgery: Caution. Unknown effect on bleeding and healing. Mitigation is a course pause 1–2 weeks before and after procedures, with the urologist informed.

Populations who should avoid Prostamax:

  • Men with known or suspected prostate cancer, including PSA above the age-specific range (e.g., >4.0 ng/mL), a PSA rise >0.75 ng/mL per year, or an abnormal digital rectal exam (manual prostate check by a clinician), until evaluated
  • Men with acute urinary retention or a post-void residual >200 mL
  • People with acute bacterial prostatitis or a urinary tract infection with fever
  • Children and adolescents under 18
  • Pregnant or breastfeeding individuals
  • People with known hypersensitivity to the peptide or to benzyl alcohol in bacteriostatic water
  • People with bleeding disorders such as hemophilia (an inherited clotting disorder), or a platelet count <100,000/µL

Risk Mitigation Strategies

  • Urologic evaluation first: PSA, digital rectal exam and urinalysis before any course prevent self-treatment of undiagnosed prostate cancer, infection or urinary retention; blood in urine, fever or weight loss can signal such disease.
  • Verified identity and purity: Only batches with third-party HPLC (high-performance liquid chromatography, a purity test) ≥98%, mass spectrometry (a molecular-weight identity test) confirming 487.5 daltons, and endotoxin testing reduce contamination and mislabeling risk.
  • Sterile reconstitution: Bacteriostatic water, alcohol-swabbed vial tops, single-use insulin syringes, refrigeration at 2–8 °C and use within 28 days reduce injection-site infection.
  • Low dose, short course: Starting at 100–200 µg daily for 10 days limits exposure to an agent with unknown human toxicity and an unresolved DNA-damage signal.
  • Rotating injection sites: Rotating abdominal sites and watching for redness, swelling or fever limits local reactions and catches early infection.
  • One change at a time: Avoiding simultaneous new prostate supplements or bioregulator stacks allows attribution of both benefit and adverse events.
  • PSA recheck: A repeat PSA at 3 months detects any unexpected rise that could reflect a growth signal or unmasked disease.

Therapeutic Protocol

  • Injectable research-peptide course: Western peptide vendors and clinics describe reconstituting a 10–20 mg vial and injecting 100 µg–2 mg subcutaneously once daily for 10–20 days. No human dose-finding study exists.
  • Patent-based dosing: Khavinson’s patent specifies 0.01–100 µg/kg intramuscularly once daily for 10–40 days; a Tomsk rat study used 20 µg/kg intramuscularly, roughly 3 µg/kg as a human-equivalent dose.
  • Rectal suppository approach: A 2017 Russian patent describes suppositories containing 0.3–1.0 mg KEDP with dimethyl sulfoxide (a penetration enhancer); no such product is registered.
  • Bovine extract bioregulators: Vitaprost and Prostatilen suppositories or tablets, popularized in Russian urology by Khavinson’s group and later Moscow urology centres, are used in 10–30-day courses and have more clinical data than the synthetic peptide.
  • Conventional pharmacotherapy: Alpha-blockers and 5-alpha-reductase inhibitors, used in mainstream urology, have large randomized trials for enlargement symptoms and known adverse-effect profiles; they are an alternative approach, not a comparator Prostamax has been tested against.
  • Time of day: No study compared timing; community protocols use one injection in the morning or evening.
  • Half-life: Unmeasured; comparable short peptides clear within minutes, while developers claim gene-regulatory effects that outlast a course by months.
  • Single versus split dose: All protocols use a single daily dose; splitting has no stated rationale.
  • Genetic polymorphisms: No variants are known to affect dosing; no pharmacogenetic data exist.
  • Sex differences: Used and studied only in men.
  • Age: Older men typically start at the low end of dosing and complete PSA testing first; no data exist beyond age 67 in humans.
  • Baseline biomarkers: Higher baseline symptom scores and lower urine flow give measurable targets; a normal baseline leaves nothing to track.
  • Pre-existing conditions: In the patent series, chronic prostatitis courses ran 10–40 days by severity; late-stage prostatitis with bladder-neck scarring responded less.

Discontinuation & Cycling

  • Short-term courses: Prostamax is used in 10–40-day courses, not as lifelong daily therapy; no data support continuous use.
  • Withdrawal effects: None reported, and the proposed mechanism predicts none.
  • Tapering: Not applicable; all protocols end courses abruptly.
  • Cycling: Community protocols repeat courses every 4–6 months; the parent extract Prostatilen was studied as 15-day suppository courses every 3 months (Al’-Shukri et al., 2006). No data show tolerance or added benefit from cycling.
  • Stopping triggers: New urinary retention, fever, injection-site infection or a PSA rise ≥0.75 ng/mL during a course can each indicate infection or undiagnosed prostate disease rather than a peptide effect.

Sourcing and Quality

  • No licensed source: No pharmaceutical-grade Prostamax is registered in any country; all supply is labelled “for research use only” and made outside drug-manufacturing oversight.
  • Formulation: Sold as lyophilized (freeze-dried) acetate salt in 10–20 mg vials; unopened vials are stored at −20 °C, protected from light and moisture.
  • Certificate of analysis: A batch-specific certificate showing HPLC purity ≥98%, mass-spectrometry identity at 487.5 daltons, and endotoxin and sterility results is the minimum.
  • Third-party testing: Independent laboratory testing of a purchased vial, rather than the vendor’s own certificate, is the only way to confirm identity and content.
  • Compounding pharmacies: Not a US Food and Drug Administration (FDA)-approved drug component and without a USP (United States Pharmacopeia) monograph, KEDP is generally not legally compoundable by US pharmacies.
  • Oral Khavinson products differ: Prostalamin (Cytamin line) and Libidon (Cytomax line) are animal prostate extracts from Institute-linked manufacturers; they are not KEDP.

Practical Considerations

  • Time to effect: The patent reports symptom changes by the end of 10–40-day courses; Prostatilen effects appeared after 2–3 injections in early series; community reports cite urine-flow changes 4–6 weeks after a course.
  • Common pitfalls: Microgram-versus-milligram dosing errors, conflating Prostamax with extract products, self-treating without PSA testing, and stacking several bioregulators at once.
  • Regulatory status: Not approved by the FDA or EMA (European Medicines Agency); sold for research use only. Tested athletes face the World Anti-Doping Agency’s ban on substances unapproved for human use.
  • Cost and accessibility: Roughly US$40–100 per 20 mg vial via gray-market vendors; no insurer covers it, and no payer incentive favouring or disfavouring it was identified.
  • Evidence provenance: All Prostamax data come from the developer’s network (institute, patent holders, Geropharm co-authors); no independent replication exists.

Interaction with Foundational Habits

  • Sleep: Indirect. No direct sleep effect is known. If nighttime urination falls, sleep continuity may improve; tracking nightly voids gives a practical measure. No sleep disruption has been reported with evening injections.
  • Nutrition: None direct. Orally ingested KEDP is likely digested into amino acids, which is why injections are used. Dietary zinc (oysters, pumpkin seeds) supports prostate secretions, and limiting evening fluids, caffeine and alcohol reduces urinary symptoms that confound assessment.
  • Exercise: None known; no blunting of training adaptations is reported. Regular aerobic activity is associated with fewer enlargement symptoms, a potentiating confounder, while prolonged cycling-saddle pressure can aggravate chronic prostatitis pain.
  • Stress management: Indirect. Chronic pelvic pain is strongly stress-linked; no cortisol data exist for Prostamax. Pelvic-floor relaxation and stress-reduction practice may add to any symptom benefit and help separate peptide effects from stress-driven flares.

Monitoring Protocol & Defining Success

Baseline testing before a first course establishes whether symptoms have a treatable cause other than benign enlargement or prostatitis and sets reference values. It includes PSA with free-PSA fraction, a digital rectal exam, urinalysis, IPSS and NIH-CPSI (National Institutes of Health Chronic Prostatitis Symptom Index, a validated 0–43 pain and urinary questionnaire) scores, uroflowmetry (urine-flow measurement), post-void residual, and kidney function.

Ongoing monitoring follows this cadence: symptom scores at the end of each course and again at 4–6 weeks, PSA and uroflowmetry at 3 months, then every 6–12 months while courses continue. Success is defined as a sustained symptom-score drop of at least 3 IPSS points or 6 NIH-CPSI points without a PSA rise. Because the evidence base is thin, an individual’s own before-and-after data are the main source of information.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
PSA (total) <2.5 ng/mL (age 40–59); stable year to year Cancer and enlargement screen Conventional cutoff <4.0 ng/mL; avoid ejaculation and cycling for 48 hours before the draw; halved by finasteride or dutasteride
Free-PSA fraction >25% of total PSA Separates benign from suspicious elevations Paired with total PSA; useful when total PSA is 4–10 ng/mL
IPSS 0–7 (mild) Tracks urinary symptoms Validated 0–35 questionnaire; 3-point change is clinically meaningful
NIH-CPSI ≤9; drop ≥6 points from baseline Tracks prostatitis pain and urinary symptoms Validated 0–43 questionnaire; NIH-CPSI is the National Institutes of Health Chronic Prostatitis Symptom Index
Peak urine flow (Qmax) >15 mL/s Objective obstruction measure Qmax is maximum flow rate; conventional concern <10 mL/s; requires ≥150 mL voided volume
Post-void residual <50 mL Detects incomplete emptying Conventional acceptable <100–200 mL; bladder ultrasound after voiding
Urinalysis No leukocytes, nitrites or blood Excludes infection and bleeding First-morning midstream sample preferred
Creatinine and eGFR eGFR >90 mL/min/1.73 m² Detects obstruction-related kidney strain eGFR is estimated glomerular filtration rate, a kidney-function estimate; conventional normal >60
Complete blood count Hemoglobin 14–16 g/dL; platelets 150–350 ×10³/µL Baseline for infection and bleeding risk Conventional ranges are wider; repeat if fever or bruising appears
Prostate volume (ultrasound) 20–30 mL Tracks enlargement over time Transrectal ultrasound most accurate; no established Prostamax target, so track change from own baseline

Qualitative markers:

  • Nighttime urination frequency (nocturia)
  • Urinary urgency and stream strength
  • Pelvic or perineal (the area between the scrotum and anus) pain intensity
  • Erectile quality and libido
  • Sleep continuity
  • Injection-site redness, swelling or pain

Emerging Research

  • No registered human trials: A ClinicalTrials.gov search (September 2026) found no registered trial of Prostamax, KEDP or prostate peptide extracts, so no NCT ID (ClinicalTrials.gov registry number) exists; men considering it rely on preclinical and patent data only.
  • Suppository formulation: A 2017 Russian patent filed by Pharm-Holding describes stable KEDP rectal suppositories for prostatitis and enlargement; a registration trial would be the first controlled test and could strengthen or weaken the case.
  • Transport mechanism: Computer docking by Khavinson et al., 2023 predicts KEDP uptake via PEPT1 and LAT2; laboratory transport and tracer studies could confirm or refute whether it reaches prostate cells at all.
  • DNA-damage question: The doubled chromosome-exchange rate reported by Dzhokhadze et al., 2012 has not been followed by standard regulatory DNA-damage assays; such testing could weaken or clear the safety concern.
  • Class trial precedent: A blinded placebo-controlled trial of the related bladder bioregulator Chitomur in men aged 62–83 with enlargement (Gomberg et al., 2013) shows the design needed for Prostamax.
  • Extract real-world data: The prospective LEVITATE study of Vitaprost in 30 men with treatment-resistant prostatitis (Pushkar et al., 2026) reported symptom improvement without adverse events, but lacked a control group.

Conclusion

Prostamax is a four-amino-acid synthetic peptide built to copy a bull-prostate extract long used in Russian prostate care, and it is now sold online to men interested in keeping their prostate healthy with age. Its appeal lies in the idea that it signals prostate tissue to behave in a more youthful way rather than simply masking symptoms.

The evidence behind it is thin. Cell and rat studies suggest less inflammation, less scarring and a smaller prostate, and two small patient series described only in the developer’s patent report relief of pelvic pain, urinary complaints and sexual problems. None of this has been tested in a randomized human trial or checked by an independent group. Nearly all the research comes from the developer’s institute, its patent holders and a company developing the product, so financial interest runs through the whole evidence base. Stronger human data exist only for the older animal extracts, and those do not automatically apply to the synthetic peptide.

On the risk side, no serious harm has been documented, but that reflects the absence of human study as much as safety. The main practical concern is product quality in an unregulated market, along with an unexplained laboratory signal of possible DNA damage, a theoretical growth effect on prostate tissue, and the chance of delaying diagnosis of prostate cancer.

For health-focused men, Prostamax remains an experimental agent whose promise rests on early laboratory work and developer-reported experience, with genuine uncertainty in both directions.

Top - Benefits - Risks - Protocol